Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 372

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 372
---
tribution pension schemes are charged to the consolidated statement of comprehensive income in the year to which they relate.

Provisions

Provisions are recognised
when the Group has a present obligation (legal or constructive) as a result of a past event; it is probable that an outflow of resources
embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

Share-based payments

The Group operates a
number of equity-settled, share-based compensation plans, under which the entity receives services from employees as consideration for
equity instruments (options) of the Group. The fair value of the employee services received in exchange for the grant of the options is
recognised as an expense. The total amount to be expensed is determined by reference to the fair value of the options granted:

| · | including any market performance conditions (including the share price); |

| · | excluding the impact of any service and non-market performance vesting conditions (for example, remaining an employee of the entity 
 over a specified time period); and                                                                                                  |

| · | including the impact of any non-vesting conditions (for example, the requirement for employees to save). |

Non-market performance
and service conditions are included in assumptions about the number of options that are expected to vest. The total expense is recognised
over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. Where vesting conditions
are

| F-36 |

| 1 | Accounting policies (continued) |

Share-based payments
(continued)

accelerated on the occurrence
of a specified event, such as a change in control or initial public offering, such remaining unvested charge is accelerated
to the income statement.

In addition, in some
circumstances employees may provide services in advance of the grant date and therefore the grant date fair value is estimated for the
purposes of recognising the expense during the period between service commencement period and grant date.

At the end of each reporting
period, the Group revises its estimates of the number of options that are expected to vest based on the non-market vesting conditions.
It recognises the impact of the revision to original estimates, if any, in the income statement, with a corresponding adjustment to equity.
When the options are exercised, the Company issues new shares. The proceeds received net of any directly attributable transaction costs
are credited to share capital (nominal value) and share premium